nuretta

Nuretta is a brand name for a medication used to treat certain types of cancer. It is a type of immunotherapy, specifically a monoclonal antibody, designed to target and destroy cancer cells. The active ingredient in Nuretta is ipilimumab, which works by inhibiting a protein called CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4). This protein helps to regulate the immune system, and by blocking CTLA-4, Nuretta enhances the activity of T cells, which are a type of white blood cell that plays a crucial role in the body's immune response against cancer.

Nuretta is approved for use in several types of cancer, including melanoma, renal cell carcinoma, and Merkel cell carcinoma. It is typically administered through an intravenous infusion. The medication is manufactured by Bristol-Myers Squibb and was first approved by the U.S. Food and Drug Administration (FDA) in 2011.

The most common side effects of Nuretta include fatigue, diarrhea, rash, and decreased appetite. Serious side effects can occur, such as immune-related adverse events (irAEs), which are reactions that occur when the immune system attacks healthy tissues. These can include colitis, hepatitis, and endocrinopathies. Patients should be closely monitored for these potential side effects.

Nuretta is available in the United States and other countries as a prescription medication. The dosage and treatment duration may vary depending on the type of cancer and the individual patient's response to the medication. It is important for patients to discuss the potential benefits and risks of Nuretta with their healthcare provider before starting treatment.